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Abstract 
AIM: To establish if a distinct urinary metabolic 
profile could be identified in Bangladeshi hepatitis-B 
hepatocellular carcinoma (HCC) patients compared to 
cirrhosis patients and controls. 
METHODS: Urine samples from 42 Bangladeshi 
patients with HCC (39 patients with hepatitis-B HCC), 
47 with cirrhosis on a background of hepatitis B, 46 
with chronic hepatitis B, and seven ethnically-matched 
healthy controls were analyzed using nuclear magnetic 
resonance (NMR) spectroscopy. A full dietary and 
medication history was recorded for each subject. 
The urinary NMR data were analyzed using principal 
component analysis (PCA) and orthogonal partial least 
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squared discriminant analysis (OPLS-DA) techniques. 
Differences in relative signal levels of the most 
discriminatory metabolites identified by PCA and OPLS-
DA were compared between subject groups using an 
independent samples Kruskal-Wallis one-way analysis 
of variance (ANOVA) test with all pairwise multiple 
comparisons. Within the patient subgroups, the Mann-
Whitney U test was used to compare metabolite levels 
depending on hepatitis B e-antigen (HBeAg) status 
and treatment with anti-viral therapy. A Benjamini-
Hochberg adjustment was applied to acquire the level 
of significance for multiple testing, with a declared level 
of statistical significance of P < 0.05.
RESULTS: There were significant differences in age 
(P  < 0.001), weight (P  < 0.001), and body mass index 
(P  < 0.001) across the four clinical subgroups. Serum 
alanine aminotransferase (ALT) was significantly higher 
in the HCC group compared to controls (P  < 0.001); 
serum α-fetoprotein was generally markedly elevated 
in HCC compared to controls; and serum creatinine 
levels were significantly reduced in the HCC group 
compared to the cirrhosis group (P  = 0.004). A three-
factor PCA scores plot showed clustering of the urinary 
NMR spectra from the four subgroups. Metabolites 
that contributed to the discrimination between the 
subgroups included acetate, creatine, creatinine, 
dimethyamine (DMA), formate, glycine, hippurate, 
and trimethylamine-N -oxide (TMAO). A comparison 
of relative metabolite levels confirmed that carnitine 
was significantly increased in HCC; and creatinine, 
hippurate, and TMAO were significantly reduced in HCC 
compared to the other subgroups. HBeAg negative 
patients showed a significant increase in creatinine 
(P  = 0.001) compared to HBeAg positive patients 
in the chronic hepatitis B subgroup, whilst HBeAg 
negative patients showed a significant decrease in 
DMA (P  = 0.004) in the cirrhosis subgroup compared 
to HBeAg positive patients. There were no differences 
in metabolite levels in HCC patients who did or did not 
receive antiviral treatment. 
CONCLUSION: Urinary NMR changes in Bangladeshi 
HCC were identified, corroborating previous findings 
from Egypt and West Africa. These findings could form 
the basis for the development of a cost-effective HCC 
dipstick screening test. 
Key words: Urinary metabolic profiling; Hepatocellular 
carcinoma; Nuclear magnetic resonance spectroscopy; 
Hepatitis B; Bangladesh
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Core tip: Previous urinary metabolic profiling studies 
using nuclear magnetic resonance (NMR) spectroscopy 
of hepatocellular carcinoma (HCC) from Egypt and West 
Africa suggested the reproducibility of an identifying 
urinary metabolic profile in HCC. Here, a Bangladeshi 
HCC cohort was studied to identify similar changes. 
Urine samples from 142 subjects with hepatitis B HCC, 
cirrhosis, chronic hepatitis B, or no history of liver 
disease were analyzed using NMR. Urinary NMR from 
HCC differed across a range of metabolites, including 
reduced hippurate and creatinine and increased carnitine 
levels, consistent with the diverse effects of liver cancer 
on metabolic pathways and the interrelationship 
with the gut microbiome. Previous findings were 
corroborated, suggesting that a panel of metabolic 
markers could form the basis of a cost-effective HCC 
dipstick screening test. 
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INTRODUCTION
The incidence of hepatocellular carcinoma (HCC) in 
Asia was estimated to be approximately 460000 in 
2000, and since then, it has been increasing every 
year[1]. Studies have shown that hepatitis B virus 
(HBV) underlies 33% of the HCC cases in the People’s 
Republic of Bangladesh, a small, but densely-populated 
country in the Indian sub-continent, bordering India 
and Myanmar[2]. Bangladesh is considered a region of 
intermediate prevalence for HBV infection, with the 
lifetime risk of HBV infection at 20%-60%[3]. While 
HBV infection is mainly transmitted during infancy and 
childhood in Bangladesh, all age groups are affected. 
It is estimated that 2 billion people, one-third of 
the world-wide population, have been infected by 
HBV[4] and that approximately 400 million people are 
living with a chronic form of the disease[5]. Chronic 
HBV results in a wide range of liver diseases, spanning 
asymptomatic acute hepatitis to HCC. Recent studies 
have concluded that serum α-fetoprotein (AFP) lacks 
sufficient sensitivity to be widely used as a surveillance 
test for HCC[6]. Ultrasound-based surveillance is 
generally considered more sensitive than AFP, but the 
quality of the images can be both equipment- and 
user-dependent[6]. In addition, these procedures are 
generally unavailable in resource-constrained countries 
of Asia and Africa that harbor a majority population 
of HBV-related cirrhosis and HCC. A simple and 
versatile biomarker for the early stages of HCC, when 
treatment would still be effective, would, therefore, 
be of considerable value, both in resource-poor 
Bangladesh and in other parts of the world with a high 
HBV prevalence. 
There has recently been considerable interest 
in analyzing the chemical composition of urine 
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to establish if one or more urinary biomarkers 
can be used to distinguish HCC from cirrhosis or 
uncomplicated chronic HBV infection. Urinary metabolic 
profiling using proton nuclear magnetic resonance 
(NMR) spectroscopy may provide objective diagnostic 
and prognostic assessment for a range of diseases[7]. It 
would be particularly valuable if subtle changes in the 
chemical composition of urine could be interpreted to 
improve early diagnosis of HCC. Diagnosis is currently 
often not made until such a late stage of disease that 
treatment measures are ineffective. Clinical cohorts 
from Egypt[8], Nigeria[9,10], and The Gambia[10] have 
been studied, and a consensus is emerging for a 
urinary fingerprint of HCC. The aim of this study was 
to establish if a similar urinary NMR fingerprint for HCC 
could be identified in a Bangladeshi cohort, since these 
patients have a different environmental and genetic 
background than the African populations.
MATERIALS AND METHODS
Study population
Urine samples were obtained with informed consent 
from patients attending the Department of Hepatology, 
Bangabandhu Sheikh Mujib Medical University, Dhaka, 
Bangladesh. Ethical approval was granted by the 
research ethics committee at Bangabandhu Sheikh 
Mujib Medical University and Imperial College London 
(REC 09/H0712/82), and the study conformed to the 
1975 Declaration of Helsinki.
A total of 152 subjects, all of Indian ethnic origin, 
were recruited for the study between January 2013 
and November 2014. The study cohort comprised 46 
patients with HCC on a background of hepatitis B (43 
patients) (HCC-HBV), hepatitis C (one patient), and 
cryptogenic (two patients); 50 patients with clinical or 
histologically confirmed hepatitis B related cirrhosis 
(CIR), 48 patients with non-cirrhotic chronic hepatitis 
B related liver disease (CHB), and eight healthy 
volunteers with no history of liver disease from the 
same Bangladeshi population (CTR). All patients with 
HBV-related HCC provided a 5-10 year history of their 
liver disease, and all were seropositive for hepatitis 
B surface antigen (HBsAg) and expressed antibodies 
to hepatitis B core antigen (anti-HBc) at the time of 
sampling. Forty two of these patients had hepatitis B 
e-antigen (HBeAg) status determined, and levels of 
HBV DNA were quantified in 35 subjects. The diagnosis 
of HCC was made from past history of HBV-related 
chronic liver disease, clinical presentation, ultrasound 
assessment of HCC nodules, and elevated AFP levels. 
The diagnosis was confirmed by fine needle aspiration 
cytology (FNAC). 
Urine sample collection and preparation for NMR 
analysis
A full dietary and medication history was recorded for 
each subject. Mid-stream urine samples were collected 
in the morning into tubes and stored at -20 ℃, 2 to 4 
h after collection, in Bangladesh until transport to the 
Institute of Hepatology, London, United Kingdom on 
dry ice and by air. Samples were prepared for NMR 
study according to previously published standard 
methodology[9]. Specifically, 400 μL of urine was added 
to 160 μL of phosphate buffer solution (0.2 mol/L 
Na2HPO4/0.2 mol/L NaH2PO4, pH 7.4) and 40 μL of 
3-trimethylsilyl-(2,2,3,3-d4)-1-propionate (TSP)/D2O 
solution. After centrifuging, 550 μL of buffered urine 
was pipetted into an NMR tube of 5 mm diameter 
(Norell 502-7 from Glass Precision Engineering 
Ltd, Leighton Buzzard, United Kingdom) for proton 
NMR spectroscopy at the Department of Chemistry, 
University College London. Samples were placed in a 
sample queue at 21 ℃ on the auto sampler, and some 
samples may have remained in the queue for up to 6 
h before NMR analysis.
Proton NMR spectral acquisition 
The urine samples were prepared for proton NMR 
study and analyzed in a random order. NMR spectra 
were recorded on a Bruker Avance III 600 NMR 
spectrometer (Billerica, MA, United States) operating 
at proton NMR frequency of 600.13 MHz equipped 
with a 5 mm DCH cryoprobe and a 60-position sample 
changer BACS60. Data acquisition and processing 
were performed using standard TopSpin (version 3.2, 
Bruker) software. NMR spectra were recorded at 300 
K. Temperature calibration was carried out using a 
sample of 99.8% deuterated methanol in a 5 mm NMR 
tube. A standard water suppression sample of 2 mmol/
L sucrose in 90%H2O + 10%D2O with 4,4-dimethyl-
4-silapentane-1-sulfonic acid (DSS) was used for 
manual iterative optimization of high-order shims 
(z6 in particular) via inspection of the shape of the 
residual water signal after presaturation. Each sample 
was shimmed using a modified topshim routine, in 
which the z shim was incremented by +24 units at 
the final stage in order to achieve optimum resolution 
for organic species dissolved in water. The increment 
applied was determined using a sample of H2O:CD3CN 
(3:1) with a small amount of DSS added to it. This 
sample was shimmed using first deuterium of CD3CN 
and then the protons of H2O. The change of the z shim 
from the shimming using CD3CN to that using H2O was 
-24 units. The deuterium lock phase was autocorrected 
both before and after shimming. The presaturation 
frequency (o1, Hz) was determined using a single 360° 
pulse sequence followed by further manual iterations 
where the phase of the pre-saturated residual water 
signal was monitored and dispersive contributions 
were minimized. This was done for the first sample for 
each set of 20-25 samples, and the o1 value was then 
kept constant for the remaining samples. The variation 
in the o1 value for all samples was found to be within 
less than ± 0.5 Hz. Similarly, probe tuning and 
matching was carried out manually for the first sample 
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was then repeated with all outliers excluded, and the 
metabolites contributing to the separation of groupings 
were identified from the loadings plot. This final data 
set was also analyzed by OPLS-DA using SIMCA v14. 
The discriminatory power of the model was validated 
using leave-one-out cross validation. An R2 value was 
determined to give a measure of the goodness of fit 
by the model. A cross-validated Q2 statistic (based on 
a 1:7 leave one out algorithm) was calculated as a 
quantitative measure of the predictability of the model 
for the Y variable, where a positive Q2 indicated a good 
predictive.
The NMR spectral regions corresponding to the 
most important discriminatory metabolite peaks, as 
determined by the PCA and OPLS-DA loadings plots, 
were normalized to the sum of the total spectral 
integral, and differences in these relative metabolite 
signal levels were compared between the subject 
groups using an independent samples Kruskal-
Wallis one-way ANOVA test with all pairwise multiple 
comparisons (IBM® SPSS® v21). Within the patient 
subgroups, the Mann-Whitney U test was used to 
compare relative metabolite levels depending on 
HBeAg status and treatment with anti-viral therapy. A 
Benjamini-Hochberg adjustment[14] was applied to the 
obtained P values to acquire the level of significance 
for multiple testing, with a declared level of statistical 
significance of P < 0.05.
RESULTS
Subject demographics
Nine samples from across the four cohorts were identified 
as outliers on subsequent NMR analysis (one CTR, two 
CHB, three CIR, and three HCC). In addition, one HCC 
subject was excluded for diagnostic uncertainty. The 
final study cohort, therefore, comprised 142 subjects 
(seven CTR, 46 CHB, 47 CIR, and 42 HCC). Subject 
demographics are summarized in Table 1, and the 
serum biochemistry results are shown in Table 2. All 
HCC patients had underlying cirrhosis, and the diagnosis 
of HCC was confirmed by FNAC in all cases. The levels 
of HBV DNA showed considerable variation. All HCC 
patients were considered to have advanced HCC, which 
is a typical finding in Bangladesh.
There were significant differences in age (P < 
0.001), weight (P < 0.001), and body mass index (BMI) 
(P < 0.001) across the four subgroups. For example, 
the CHB cohort was significantly younger than both 
the CIR (P = 0.000) and HCC (P < 0.001) cohorts, 
and BMI was significantly lower in the HCC cohort 
compared to the CTR (P = 0.001) and CIR (P < 0.001) 
cohorts. While 83% of the CIR subgroup was male, 
the control group was entirely male, and so the urinary 
NMR data were analyzed both as a complete cohort 
and as a subset of males only.
The majority of subjects had eaten a similar diet of 
rice, dhal, water with vegetables, fish or chicken, in the 
in each set of 20-25 samples and then kept unchanged 
for the remaining samples of the set. Proton NMR 
spectra with water presaturation during relaxation 
delay were acquired using a standard pulse sequence 
noesygppr1d, which suppressed effectively the probe 
background signal, giving a flat baseline. In addition, a 
digital filter (known as “BASEOPT” under TopSpin) with 
a pre-optimized correction for filter delay (1.0 μs in 
our case) was used to give spectra with a flat baseline, 
which required no first order phase correction. Prior 
to the start of data acquisition for each sample, the 
90° pulse was determined (typically 14.0 μs) and the 
power level was adjusted for a 25 Hz-wide solvent 
presaturation automatically. Four dummy scans were 
used for equilibration followed by 64 scans collected 
into 144 K points with a total repetition time of 8.0 s at 
each scan (acquisition time = 4.0 s; relaxation delay = 
4.0 s). NMR spectra were processed using the Bruker 
AMIX data processing package and the KnowItAll 
Informatics System v9.0 (Bio-Rad, Philadelphia, PA, 
United States). The Free Induction Decays were zero-
filled, and an exponential 0.3 Hz line-broadening 
function was applied before Fourier transformation. 
All NMR spectra were automatically phased, and a 
baseline correction was applied. The TSP peak was 
assigned to be at δ 0.00 ppm for an internal chemical 
shift reference. NMR peaks in the range δ 0.50-9.50 
ppm were analyzed, although the region δ 4.50-6.40 
ppm was excluded to remove the residual water signal 
and the signal from urea. The urinary NMR peaks 
were assigned to metabolites on the basis of chemical 
shifts and coupling patterns and with reference to the 
published literature[8-13].
Statistical analysis
Demographic and blood biochemistry data between 
subject groups were compared using an independent 
sample Kruskal-Wallis one-way analysis of variance 
(ANOVA) test with pairwise multiple comparisons 
(IBM® SPSS® v21), and a P value of < 0.05 was con-
sidered significant.
The NMR data were analyzed using principal 
component analysis (PCA) (KnowItAll Informatics 
System v9.0) and orthogonal partial least squared 
discriminant analysis (OPLS-DA) techniques [SIMCA 
v14 (Umetrics AB, Umeå, Sweden)]. Using the 
intellibucketing option in KnowItAll v9.0, the NMR spectra 
were subdivided into smaller regions of about 0.02 
ppm. Regions corresponding to particular metabolites 
were additionally selected, including those assigned to 
hippurate (7.82-7.85 ppm, 7.61-7.66 ppm, 7.52-7.58 
ppm); creatinine (3.0425-3.0550 ppm, 4.04-4.07 ppm); 
creatine (3.035-3.0425 ppm); citrate (2.64-2.72 ppm, 
2.52-2.58 ppm), and dimethylamine (2.72-2.74 ppm). 
All spectral regions were integrated, normalized to the 
sum of the total spectral integral, and mean-centred 
prior to multivariate analysis. PCA was performed to 
highlight outliers and clustering (KnowItAll v9.0). PCA 
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6 h prior to collection of a urine sample. The patients 
reported a varied drug history: the majority of the CHB 
group were taking multivitamins, although some were 
also taking an oral antiviral drug (n = 10, entecavir 
or tenofovir) and/or an oral proton pump inhibitor 
(PPI) (omeprazole, pantoprazole); the CIR group 
reported a combination of non-absorbable sugars 
(lactulose), PPI (omeprazole, pantoprazole), oral 
antiviral (n = 7, entecavir, tenofovir or telbivudine), 
and/or multivitamins; and the HCC cohort reported a 
wider range of medication, including an oral antiviral 
(entecavir, tenofovir), hormonal therapy (tamoxifen), 
PPI (omeprazole, pantoprazole), beta blockers, non-
absorbable sugars (lactulose), multivitamins, and pain 
killers (including tramadol). 
Serum biochemical analysis
The median (range) values for the available serum 
alanine aminotransferase (ALT), alkaline phosphatase 
(ALP), bilirubin, albumin, AFP, and creatinine levels are 
summarized in Table 2. Serum ALT was significantly 
higher in the HCC group than controls (P < 0.001) and 
patients with CHB (P < 0.001) or CIR (P = 0.006); 
serum ALP was higher in the HCC group than the 
CHB group (P < 0.001). Serum AFP was generally 
markedly elevated in HCC, although two HCC patients 
showed AFP ≤ 20 ng/mL in the presence of large 
space occupying lesion(s) in the right lobe of the liver 
as observed on axial imaging. Serum creatinine levels 
were significantly lower in the HCC group than in the 
CIR group (P = 0.004). 
Representative urinary NMR spectra
Illustrative urinary proton NMR spectra from each of 
the four subject groups are summarized in Figure 1. 
The spectral resolution was defined by a TSP linewidth 
of < 1 Hz in all NMR data sets. On visual inspection, 
a number of trends could be seen across the groups, 
including a reduction in hippurate and an increase in 
creatine, when comparing CTR, CHB, and CIR through 
to HCC (Figures 1A-D and 1A’-D’, respectively).
Analyses of the urinary NMR spectra
Nine outliers were identified on five iterations of PCA: 
one CTR showing particularly high levels of hippurate; 
two CHB showing high levels of glucose and lactate 
and overlap of creatinine into the creatine peak; three 
CIR showing either high glucose, high glucose and 
lactate, or ethanol present; and three HCC showing 
either paracetamol resonances, absence of creatine 
and creatinine, or unassigned additional dominant 
peaks. 
A three-factor PCA score plot of the final study 
cohort of 142 subjects is illustrated in Figure 2, 
showing clustering of each of the four subgroups. 
Metabolites that contributed to the discrimination 
between groups in the loadings plot included acetate, 
creatine, creatinine, dimethyamine (DMA), formate, 
glycine, hippurate, and trimethylamine-N-oxide 
(TMAO). An OPLS-DA plot is illustrated in Figure 3 and 
the R2(X), R2(Y) and Q2 values were 0.468, 0.289, and 
0.195, respectively.
Acetate, carnitine, citrate, creatine, creatinine, 
Table 1  Subject demographics of the Bangladeshi study cohort  
Group n Age (yr), 
median 
(range)
M:F (%male) Etiology, n HBeAg 
positive
Height (cm), 
median (range)
Weight (kg), 
median (range)
BMI (kg/m2), 
median (range)
CTR   7 37 (24-46)     7:0 (100%) NA NA 170 (152-173) 65 (54-85) 26.0 (18.7-29.4)
CHB 46 27 (15-45) 40:6 (87%)     HBV (100%) 27 166 (147- 180) 55 (35-79) 20.6 (13.9-26.6)
(-59%)
CIR 47 42 (15-67) 39:8 (83%)   HBV (98%) 21 165 (142–175) 58 (42-82) 21.9 (14.9-29.3)
Cryptogenic HBV (2%) (-45%)
HCC 42 48 (27-90) 38:3 (90%)   HBV (93%) 15 162 (145-180) 48 (38-75) 18.3 (12.3-25.2)
HCV (2%) (-36%)
Cryptogenic (5%)
CTR: Healthy controls; CHB: Chronic hepatitis-B related liver disease; CIR: Cirrhosis; HCC: Hepatocellular carcinoma; NA: Unavailable; BMI: Body mass 
index.
Table 2  Serum biochemistry profiles
Group ALT ALP Bil Alb AFP Creatinine
(U/L) (U/L) (mg/dL) (g/dL) (ng/mL) (mg/dL)
CTR 31 (18-42) [7/7] NA NA NA NA NA
CHB 40 (22-232) [32/46] 96 (63-171) [14/46] 1.4 (0.4-2.2) [5/46] 3.4 (2.9-3.9) [2/46] NA 1.4 (1.3-1.5) [2/46]
CIR 51 (10-243) [30/47] 286 (75-558) [5/47] 1.9 (0.3-22.4) [19/47] 2.7 (1.5-39.0) [20/47] 6 (2-12) [4/47] 1.4 (0.8-2.8) [17/47]
HCC 74 (28-332) [32/42] 259 (82-648) [25/42] 1.8 (0.3-21.5) [28/42] 3.1 (1.3-35.0) [26/42] 4900 (4-70000) [34/42] 0.9 (0.4-1.3) [23/42]
Data are represented as median (range) [number of subjects included/total number of subjects in subgroup]. CTR: Healthy controls; CHB: Chronic 
hepatitis-B related liver disease; CIR: Cirrhosis; HCC: Hepatocellular carcinoma; ALT: Alanine transaminase; ALP: Alkaline phosphatase; Bil: Bilirubin; 
Alb: Albumin; AFP: α-fetoprotein; NA: Unavailable.
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DMA, hippurate, and TMAO metabolite levels were 
significantly different across the four groups, when 
considering all subjects (Table 3) and only the males. A 
comparison of relative metabolite levels between HCC 
vs CTR and/or HCC vs CHB in all subjects confirmed 
that carnitine was significantly increased in HCC, and 
creatinine, hippurate, and TMAO were significantly 
reduced in HCC (Figure 4). A significant increase in 
carnitine and significant reductions in creatinine and 
hippurate were observed in the HCC group compared 
to the CIR group (Figure 4).
HBeAg negative patients showed a significant 
increase in creatinine (P = 0.001) compared to HBeAg 
positive patients in the CHB subgroup. In the CIR 
group, HBeAg negative patients showed a significant 
decrease in DMA (P = 0.004) compared to HBeAg 
positive patients; there were no significant differences 
in the HCC subgroup according to HBeAg status.
There were no differences in metabolite levels in 
the HCC or CHB groups when comparing subjects 
receiving antiviral treatment with those not. However, 
creatine levels were lower in subjects receiving 
antiviral therapy in the CIR group (n = 7) than those 
who were not (n = 40) (P = 0.002).
DISCUSSION
In this study of Bangladeshi subjects, all of Indian 
ethnic origin, the urinary NMR metabolic profile 
measured in patients with HCC was distinguishable 
from the urinary profile of patients with CIR and CHB 
and also healthy control subjects. The majority of the 
patients (131 patients) had a background of CHB, 
while one patient with cirrhosis and two patients with 
HCC were defined as cryptogenic and one HCC subject 
had a background of HCV. Metabolites that contributed 
to the differences in urinary NMR profiles of HCC, 
compared to CIR, CHB and/or CTR, included acetate, 
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Figure 1  Illustrative urinary proton nuclear magnetic resonance spectra. 
From a 35 year old healthy control (CTR) (A, A’); a 22 year old male with 
chronic hepatitis-B related liver disease (CHB) (B, B’); a 36 year old male with 
hepatitis B virus (HBV)-cirrhosis (C, C’); and a 50 year old male with HBV-
hepatocellular carcinoma (AFP > 30000 mg/dL) displaying (A-D) the aliphatic 
region 0.5-4.5 ppm and (A’-D’) the aromatic region 6.4-9.5 ppm (D, D’). Each 
NMR spectrum is scaled independently. The more prominent peaks are 
assigned and include acetate (Ace), carnitine (Car), citrate (Cit), creatine (Cr), 
creatinine (Crn), dimethylamine (DMA), formate (For), glycine (Gly), hippurate 
(Hip), histidine (His), and trimethylamine-N-oxide (TMAO). 
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Figure 2  A three-factor principal components analysis scores plot of 
the cohort of 142 subjects and clustering of each of the four subgroups. 
A: Principal components analysis (PCA) scatter plot showing clustering and 
separation of healthy controls (CTR), chronic hepatitis-B related liver disease 
(CHB), cirrhosis (CIR), and hepatocellular carcinoma (HCC) subgroups; B: 
The associated loadings plot illustrating the metabolites contributing to the 
separation of the subgroups.
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carnitine, citrate, creatine, creatinine, DMA, hippurate, 
and TMAO. Within the CHB and CIR patient subgroups, 
metabolite differences were also observed according to 
HBeAg status and, only in CIR, to treatment with oral 
antiviral therapy. 
Our findings extend previous studies using urinary 
NMR to identify metabolic changes in HCC. Previous 
studies showed that urinary NMR changes in HCC 
could be distinguished from CIR and CTR in patient 
cohorts from Egypt, Nigeria, and The Gambia, with 
HCC on a background of either chronic HCV[8,10] or 
chronic HBV[9,10]. An NMR pattern has emerged to 
separate HCC from CIR and CTR, which includes a 
reduction in hippurate, citrate, creatinine, and TMAO 
and an increase in acetate, carnitine, and creatine. 
In this population, neither glycine nor formate was 
significantly different in HCC between the other study 
cohorts, although both of these metabolites were 
identified as discriminators in the West African study. 
Overall, given that the urinary profile of HCC could 
be distinguished from CIR, CHB, and CTR, this study 
provides further support for the suggestion that a 
diagnostic marker may be feasible, as consistent 
urinary NMR changes are seen across differing eth-
nicities as well as varying disease etiologies. 
The urinary metabolite changes observed in HCC 
subjects relate to alterations in both host and gut 
bacterial metabolism. For example, a reduced urinary 
concentration of citrate, which is a tricarboxylic acid 
intermediate, might be in agreement with Warburg’s 
hypothesis of altered mitochondrial aerobic respiration 
and heightened physiological stress of cancer cells[8]. 
The alterations observed in carnitine are interesting, 
and its increase in HCC is consistent with the previous 
urinary NMR profiling studies in HCC[8-10]. Carnitine is 
required for energy metabolism, enabling fatty acids 
to enter the mitochondria for β-oxidation[15]. Carnitine 
can be absorbed from the diet or synthesised in the 
liver, testis, and kidney and reabsorbed via the renal 
system[8]. Increased urinary carnitine may, therefore, 
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Figure 3  Scores plot of orthogonal partial least squares discriminant analysis (OPLS-DA) model of CTR, CHB, CIR, and HCC subgroups. R2(X), R2(Y) and 
Q2 values were 0.468, 0.289, and 0.195, respectively.
CTR
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Table 3  Comparison of relative signal levels (mean ± SD) of discriminatory metabolites between study cohorts1
Selected metabolites Study cohort (number of subjects in group) P  value2
Metabolite δ/ppm (multiplicity) 
of peak analysed
CTR (n  = 7) CHB (n  = 46) CIR (n  = 47) HCC (n  = 42)
Acetate 1.92 (s)   0.34 ± 0.03   0.57 ± 0.64 1.70 ± 2.14 1.24 ± 1.49 0.007
Carnitine 3.23 (s)   0.57 ± 0.41   0.42 ± 0.22 0.44 ± 0.53 1.19 ± 1.04 0.000
Citrate 2.52 (d)   1.49 ± 0.61   1.35 ± 0.61 1.19 ± 1.21 1.07 ± 0.46 0.005
Creatine 3.03 (s)   1.34 ± 0.35   1.24 ± 0.38 1.07 ± 0.95 1.54 ± 1.82 0.007
Creatinine 3.04 (s) 10.88 ± 1.30 10.06 ± 1.76 7.74 ± 3.00 5.85 ± 1.83 0.000
DMA 2.72 (s)   2.14 ± 0.57   2.11 ± 0.58 1.95 ± 1.21 1.91 ± 0.45 0.022
Formate 8.46 (s)   0.07 ± 0.03   0.07 ± 0.05 0.16 ± 0.16 0.16 ± 0.18 0.059
Glycine 3.56 (s)   1.04 ± 0.39   0.84 ± 0.42 0.74 ± 0.38 0.79 ± 0.63 0.129
Hippurate 7.85 (d)   0.99 ± 0.47   0.85 ± 0.47 0.44 ± 0.35 0.28 ± 0.30 0.000
TMAO 3.27 (s)   1.79 ± 0.44   1.95 ± 0.77 1.62 ± 1.04 1.32 ± 0.75 0.000
1Percentage normalised metabolite signal level relative to total NMR signal in the region 0.50-9.50 ppm (excluding 4.50-6.40 ppm); 2Significance for 
independent samples Kruskal-Wallis one-way ANOVA test with pairwise multiple comparisons. CTR: Healthy controls; CHB: Chronic hepatitis-B related 
liver disease; CIR: Cirrhosis; HCC: Hepatocellular carcinoma. 
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correspond to excess carnitine ingestion, increased 
biosynthesis, or poor reabsorption and may reflect 
overproduction of tumor carnitine to maintain rapid 
growth and fuel mitochondrial activity[8]. Further 
evidence of heightened β-oxidation is shown by 
relatively higher acetate in the urine of HCC patients 
than in controls[10]. Advanced HCC can be complicated 
by cancer cachexia with associated sarcopenia, and 
urinary creatinine concentration has been suggested 
as a biomarker of sarcopenia[16]. In combination 
with other factors, however, urinary NMR creatinine 
concentration may contribute to a biomarker panel for 
HCC. Our findings on urinary creatine suggest that it is 
elevated in HCC in comparison to ethnically-matched 
healthy controls but is reduced in CIR patients in 
comparison to the same controls. Creatine has a direct 
function in cellular energy transport, and it may be 
that creatine is elevated in rapidly growing cells; and, 
indeed, urinary creatine levels may be increased 24 h 
after partial hepatectomy in rats[17]. 
The urinary changes in DMA, hippurate, and TMAO 
implicate alterations in the gut microbiome. TMAO 
is the oxidation product of trimethylamine (TMA), 
which can be produced by bacterial degradation of 
dietary phosphatidylcholine and choline. It is likely 
that a decrease in TMAO reflects dysregulation of the 
intestinal microbiota. DMA can also be a product of 
gut bacterial metabolism of dietary choline, although it 
can originate from the N-methylation of methylamines 
from the breakdown of creatine. While diet was not 
controlled for in the study, and such a proposition 
would be difficult to implement, the observation 
that HBeAg status has an influence on DMA levels 
does further suggest that gut bacterial metabolism 
Figure 4  Boxplots of selected metabolites. Metabolites [acetate, carnitine, creatinine, dimethylamine (DMA), hippurate, and trimethylamine-N-oxide (TMAO)], 
showing the results of a comparison of signal levels (normalized to 1) using an independent-samples Kruskal-Wallis test.
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might have pathophysiological consequences in CHB 
and HCC. Hippurate is formed by the conjugation of 
benzoate with glycine in liver and kidney mitochondria. 
Benzoate is formed from dietary aromatic compounds 
via gut microbial metabolism. It has been suggested 
that less efficient benzoate conjugation and lower 
urinary hippurate excretion levels may result from 
reduced hepatic function in patients with HCC[8]. 
The differences observed in the urinary profiles 
according to HBeAg status within the CHB and CIR 
subgroups are worth exploring in more detail in future 
studies. In this cohort, differences were seen in DMA 
and creatinine levels between HBeAg positive and 
negative subjects in the CHB and CIR subgroups 
respectively. The rate of disease progression has 
been shown to be influenced by HBeAg status[18], and 
it would be particularly interesting if these urinary 
metabolic differences could be attributed to differences 
in cell turnover, for example.
An impact of antiviral treatment on relative urinary 
creatine levels was observed in patients with cirrhosis. 
While antiviral therapy may influence renal function[19], 
it is not clear why urinary creatine levels might be 
altered. Regardless, any influence of treatment effects 
do need to be considered when interpreting the urinary 
metabolite changes.
There are a number of limitations to this present 
study. There was a logistical delay between sample 
collection and sample analysis, as the Bangladeshi 
samples were archived, stored, and transported to 
London for NMR analysis, although this would not be 
expected to have had any impact on the urinary NMR 
profile. The NMR urinary profile from nine subjects 
were shown to be outliers using PCA, and confounding 
factors included high levels of glucose and overlapping 
peaks from unreported over-the-counter medication. 
These factors need to be considered for developing 
an NMR analysis protocol for inclusion of all NMR 
data sets, without obscuring overlapping peaks in 
the spectral regions with outlier resonances. There 
was gender imbalance between the subgroups, but 
analyzing males only as a separate cohort did not alter 
the urinary NMR differences seen across the patient 
groups. Increased study numbers would allow inclusion 
of training and validation data sets and also a more 
detailed comparison of NMR findings with currently 
available diagnostic serum and clinical biomarkers. 
Further prospective studies looking at the urinary NMR 
differences in patients with early HCC, for example 
stage 0 using the Barcelona Clinic Liver Cancer score[20] 
and also following treatment, would underline the 
potential of implementing a urinary screening test for 
HCC. 
In conclusion, urinary NMR changes in HCC are 
consistent with the diverse effects of liver cancer on 
human physiology and gut bacterial action and may 
aid the development of a cost-effective HCC urinary 
dipstick screening test. Such a diagnostic urine test 
for HCC could be a paradigm shift in liver cancer 
screening. It could provide a practical and cost-
effective test that is easy to use in primary care and 
particularly applicable to countries of Central and 
East Asia. Clinically and economically, such a simple 
approach could have a major impact, not only in the 
developed economies of Europe and North America, 
but also in severely resource limited settings, such as 
sub-Saharan Africa. Further validation work is required, 
but the pattern emerging from different studies around 
the world is promising.
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